Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle
Liquidia (LQDA) shares jumped 42% after the company reached a $380.7M settlement with United Therapeutics (UTHR), resolving six ongoing lawsuits and securing continued commercialization of YUTREPIA for pulmonary arterial hypertension.
Under the agreement, Liquidia will pay $175M within 30 business days, followed by two $72.7M installments due
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.